Ajooni Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

Results View source PDF Explain this filing

AJOONI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.3%Reaction day

₹5.92

prior close

₹5.97

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+0.4% vs market

Food Products peers, median of 77sector · industry level-0.1%+0.4% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250 and 0.4 pts more than its Food Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.3

15m

-0.3

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.3-0.1+0.4-0.1+0.4

Next day

+0.2+0.2-0.1+0.2-0.0

+0.3+0.6-0.3+0.8-0.5

-0.5+0.9-1.4-0.1-0.4

-0.7+1.0-1.7-0.0-0.7

-1.2+0.7-1.9+0.1-1.2

-2.7+1.8-4.5+1.1-3.8

15d

-5.1+1.7-6.8-0.6-4.5

+1.7+3.1-1.4+2.6-1.0

-7.1+1.7-8.8+2.7-9.8

-8.8-1.0-7.7-2.2-6.5

UpDownMarket · Nifty Microcap 250Sector · Food Products peers, median of 77Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ajooni Biotech Limited has submitted its financial results for the period ended March 31, 2025 to the NSE. The announcement is a standard filing notification and does not include specific financial figures or auditor remarks in the headline. Investors would need to refer to the detailed results document or the company's filings to review the actual numbers, including revenue, profit/loss, and any audit observations. No comparative data or year-on-year context is provided in this brief notice.

Likely market impact

This is a routine regulatory submission with no immediate price-moving information in the headline; shareholders should review the detailed results for insights into the company's performance.